Navigation Links
Numira Biosciences Names New Board Member
Date:3/5/2008

Drug discovery and development veteran Paul Grint, M.D. brings extensive

experience to Numira

IRVINE, Calif., March 5 /PRNewswire/ -- Numira Biosciences announced the appointment of Paul Grint, M.D., to its Board of Directors.

Currently, Dr. Grint serves as the Chief Medical Officer and Head of Development at Kalypsys, Inc., a drug discovery and development company based in San Diego, CA. Prior to Kalypsys, he held senior management positions at Zephyr Sciences, Pfizer Global Research & Development, IDEC Pharmaceuticals, and Schering-Plough. Additionally, he is a member of the Board of Directors at Illumina Inc. and serves as Chairman of the Advisory Council of the Keck Graduate Institute.

"We are very pleased to have attracted an industry leader of Dr. Grint's caliber," said Michael Beeuwsaert, President and CEO of Numira. "His extensive background in drug discovery and development will be invaluable to us as we head into our next phase of growth."

About Numira Biosciences

Numira Biosciences is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high-value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy, and toxicity.

For more information, please visit the company's website at http://www.numirabio.com.


'/>"/>
SOURCE Numira Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Dr. Rod J. Rohrich, Dallas ... the Department of Plastic Surgery at UT Southwestern ... grafting, and modern lift-and-fill facelifts before colleagues at ... by the American Society of Plastic Surgeons (ASPS). ... structure were explored in detail during Dr. Rohrich's ...
(Date:11/26/2014)... By Amy Norton ... -- While people have long believed their dogs understand what ... meaning and emotion of words in a human-like way. ... of human speech -- including the actual content and the ... team,s findings give a deeper insight into the canine brain, ...
(Date:11/26/2014)... Nov. 26, 2014 (HealthDay News) -- More than half ... their thinking and memory skills, a new study suggests. ... Neurology , "approximately 1.8 million Americans over the age ... of their cognitive [mental] abilities," study author Dr. Vikas ... Ann Arbor, said in a journal news release. ...
(Date:11/26/2014)... Deptford, NJ (PRWEB) November 26, 2014 ... and Lourdes Cardiology have launched a partnership designed ... readmission rates for congestive heart failure (CHF) patients ... Deptford Center staff and Lourdes Cardiology team will ... developed and supervised protocols. This partnership pairs the ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used ... that looks and acts similar to asbestos-induced mesothelioma. Surviving ... research. Click here to read it now. ... Experimental Medicine in Hannover injected 500 lab rats with ... eventually developed mesothelioma , how quickly it developed ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3Health News:Too Few Americans Undergo Dementia Screening 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2
... , , NASHVILLE, ... $11.6 and $18 billion in diagnostic imaging costs over the ... program similar to those used in the private sector. Currently, ... billions of dollars. According to an independent analysis released today ...
... , , , ... , , FAIRFAX, Va., July 16 ... a cancer survivor in the Chicago area who has dedicated his or ... winner of the Survivor Circle Award will receive $1,000 and be honored ...
... , The hospital is the highest-rated Illinois ... , CHICAGO, July 16 Northwestern Memorial Hospital is ... ranked in Illinois -- as part of U.S. News & World Report,s 2009 ... guide evaluated 4,861 medical centers nationwide and 174 were chosen and ranked according ...
... get LASIK, researchers say , THURSDAY, July 16 (HealthDay ... surgery may benefit from implantable lenses made of a ... LASIK "has gained widespread popularity as a safe and ... with high [severe] myopia or thin corneas face some ...
... , , , ... www.STDTestExpress.com ) offers leading direct-to-consumer testing services for sexually ... on the Internet to have partnered with a telemedicine network ... to order these specialty tests, discuss STD symptoms, review test ...
... 16 Enigma Diagnostics Limited, the decentralized and point-of-care molecular ... license agreements with Roche Molecular Systems, Inc. (RMS). , ... July 2009, provide Enigma full access under patents owned or ... PCR chemistry and melt analysis and will allow Enigma to ...
Cached Medicine News:Health News:Radiology Benefit Management Could Save Medicare up to $18 Billion Over 10 Years 2Health News:Radiology Benefit Management Could Save Medicare up to $18 Billion Over 10 Years 3Health News:Award Honors Chicago Cancer Survivor Who Gives Back 2Health News:Award Honors Chicago Cancer Survivor Who Gives Back 3Health News:Award Honors Chicago Cancer Survivor Who Gives Back 4Health News:Northwestern Memorial Among America's Best Hospitals in 11 Clinical Specialties According to U.S. News' 2009 Rankings 2Health News:Northwestern Memorial Among America's Best Hospitals in 11 Clinical Specialties According to U.S. News' 2009 Rankings 3Health News:New Option for Correcting Nearsightedness 2Health News:STD Test Express Offers Free Doctor Consultations With Every STD Test 2Health News:Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc. 2
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... THOUSAND OAKS, Calif. and LONDON ... AMGN ) and AstraZeneca (NYSE: AZN ) today ... trial evaluating two doses of brodalumab in more than 1,800 ... compared with both Stelara ® (ustekinumab) and placebo at ... the brodalumab weight-based analysis group were each shown to be ...
(Date:11/26/2014)... SAN DIEGO , Nov. 25, 2014 Halozyme ... at the Piper Jaffray Healthcare Conference in New ... p.m. EDT/10:00 a.m. PDT . Dr. Helen Torley ... overview. The presentation will be webcast through the ... and a recording will be made available for 90 days ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... the Study of the ... Liver Annual Meeting -, SAN FRANCISCO, April ... 2 study of its lead,compound, MitoQ(R) (mitoquinone) in liver disease. The results ... of the Liver,(EASL) Annual Meeting, being held April 23 - 27 in ...
... at the 10th Annual Superbugs and Superdrugs Conference on ... ... Mass., April 10 Enanta Pharmaceuticals, a,leader in the development ... breakthrough research program to,evaluate a new macrolide-related drug class, Bicyclolides, ...
Cached Medicine Technology:Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R) 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with our displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless...
... The modular Doro headrest ... invasive and non-invasive applications in ... can be adapted to all ... the decisive advantages and improvements ...
Mc Kenzie twist drill, diameter 13 mm....
Hudson Brace, snap lock chuck....
Medicine Products: